Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
August 09 2021 - 4:01PM
Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage
biopharmaceutical company focused on the development and
commercialization of transformative therapies for patients living
with central nervous system (CNS) diseases with high unmet medical
needs, today announced it will host a live webcast on Monday,
August 16, 2021 at 8:30 a.m. ET to report its second quarter 2021
financial results and provide a business update.
A live webcast of the event will be available on
the Investors section of the Impel NeuroPharma website at
https://investors.impelnp.com/. A replay of the webcast and
accompanying slides will be available on the Impel NeuroPharma
website following the event.
About Impel NeuroPharma
Impel NeuroPharma, Inc. is a late-stage
pharmaceutical company focused on utilizing its proprietary
technology to develop and commercialize transformative therapies
for people suffering from diseases with high unmet needs, with an
initial focus on diseases of the CNS. The Company’s strategy is to
rapidly advance its product candidate pipeline that pairs its
proprietary Precision Olfactory Delivery (POD®) system with
well-established therapeutics, including TRUDHESA™ for the acute
treatment of migraine, INP105 for the acute treatment of agitation
and aggression in patients with autism, and INP107 for OFF episodes
in Parkinson’s disease.
Investor Relations:Christina
TartagliaStern Investor RelationsPhone: (1)
212-362-1200Email: christina.tartaglia@sternir.com
Media Relations:Melyssa
WeibleElixir Health Public RelationsPhone: (1) 201-723-5805Email:
mweible@elixirhealthpr.com
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Impel Pharmaceuticals (NASDAQ:IMPL)
Historical Stock Chart
From Jul 2023 to Jul 2024